Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,018 total articles
Cadrenal Therapeutics' CEO, Pham Quang X, conducted two transactions selling common stock in late May and early June. This activity occurred while the stock traded near its 52-week low. Despite the insider sales, the company reported improvements in net loss figures and received critical guidance from the FDA to advance its investigational drug can…
Thomas John, a director at GENELUX Corp (NASDAQ:GNLX), completed a stock sale totaling $29,801. The sale involved 10,000 shares of the company's common stock on June 1, 2026. While this transaction was executed through an established Rule 10b5-1 trading plan, which Mr. John initiated on June 4, 2025, the current market price for GNLX is noted at $2…
Guidewire Software, Inc. (NASDAQ:GWRE) CEO Michael George Rosenbaum recently sold 1,200 shares of company stock for a total value of $190,703 on June 1, 2026. This transaction was executed under a pre-scheduled 10b5-1 trading plan. Despite the executive sale and some valuation concerns noted by analysis platforms, Guidewire reported robust fiscal s…
Benjamin C. Singer, Chief Legal Officer and Secretary of Procore Technologies, Inc., recently sold a block of common stock shares. This activity is reported alongside mixed results from the company's first-quarter 2026 earnings report. Although revenue exceeded expectations, the lower-than-anticipated earnings per share prompted caution from analys…
The recent activity of director Lauren Elaina Friedman, which included the sale of $505,730 worth of Class A Common Stock in Palantir Technologies Inc. (NYSE:PLTR), provides context against a backdrop of robust financial reporting and varied expert opinions. The sales occurred on May 29 and June 1, 2026, utilizing a Rule 10b5-1 trading plan establi…
CoreWeave's director, Jack D. Cogen, recently executed a substantial sale of Class A Common Stock shares totaling over $29 million. Despite this insider transaction, the company continues to report strong market momentum, coupled with recent announcements regarding significant financing rounds, advanced technology integration, and positive analyst …
Christopher Peetz, the CEO of Mirum Pharmaceuticals, Inc., recently executed a series of stock sales following the exercise of employee options. These actions occurred after the company's shares had seen significant appreciation over the past year. Separately, Mirum announced plans for a major private placement of senior notes and received positive…
A director at Mirum Pharmaceuticals, Inc. executed a sale of company shares totaling $397,700 after an earlier vesting event. This transaction occurred against a backdrop of significant corporate activity, including the announcement of new convertible senior notes and elevated price targets from major research firms regarding its key drug candidate…
Vivek K. Jayaraman, the Chief Operating Officer of CERUS CORP (NASDAQ:CERS), sold common stock valued at $50,001 on May 29, 2026, through a pre-arranged trading plan. This transaction occurred against a backdrop of recent positive financial news, as Cerus Corporation reported first-quarter earnings that surpassed market expectations for both revenu…
Andrew H. Rubenstein, the Chief Executive Officer and President of Accel Entertainment, Inc., executed significant stock sales in June 2026. These transactions were conducted under a prearranged trading plan (Rule 10b5-1). Concurrently, the company reported its Q1 2026 financials, detailing record revenue of $352 million, although earnings per shar…
Nurix Therapeutics' Chief Legal Officer, Christine Ring, recently sold a significant amount of common stock through an established Rule 10b5-1 trading plan. Simultaneously, the company generated substantial investor interest by presenting promising clinical data for its drug candidates, leading several major analyst firms to revise their ratings an…
R. David Banyard, Jr., the Chief Executive Officer and President of MasterBrand, Inc., recently acquired a block of common stock. This transaction occurred against a backdrop of mixed financial performance for the company in the first quarter of 2026, which fell short of analyst projections. The report details Mr. Banyard's holdings and highlights …
The recent transactions involving Matador Resources Co's Senior Vice President and Chief Accounting Officer, Benjamin T. Colodney, alongside the company's operational updates, point to significant strategic activity. Key developments include Mr. Colodney's purchase of shares via his 401(k) plan and a substantial land acquisition in the Delaware Bas…
The recent activity of key executives at RingCentral, Inc. (RNG), including the sale of shares by Chief Accounting Officer Tarun Arora, occurred against a backdrop of strong first-quarter financial reporting. While RNG reported better-than-expected earnings and revenue for Q1 2026, the company's stock experienced an after-hours decline, suggesting …
Vaibhav Agarwal, the Chief Financial Officer of RingCentral, Inc. (NASDAQ:RNG), recently executed notable stock transactions involving both sales and grants of common stock. These actions occurred while the company reported strong financial results for the first quarter of 2026. The Q1 report showed that RingCentral surpassed market expectations in…
Simrat Randhawa, Executive Vice President and Head of Research & Development at Dianthus Therapeutics, Inc., executed a transaction involving the sale of approximately $2.4 million worth of company common stock on June 1, 2026. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan following the exercise of stock options. The arti…
Mark Coleman, a director at Axsome Therapeutics, Inc., recently executed multiple sales totaling 17,537 shares of common stock, valued at approximately $4.02 million. These sales, which occurred between May 29 and June 2, 2026, were conducted under an established trading plan. The activity takes place as AXSM stock trades near its historical highs,…
A director of Star Equity Holdings purchased additional shares of common stock in late May 2026. This transaction occurs against a backdrop of ongoing corporate activities, including an At Market Issuance Sales Agreement for preferred stock, updated executive compensation plans, and the completion of a significant sale-leaseback transaction involvi…
Alignment Healthcare, Inc. (NASDAQ:ALHC) saw its President - MSO, Mark D. Kent, acquire a significant block of common stock in early June 2026. This transaction occurred alongside the release of robust first-quarter 2026 financial results and several key leadership appointments at the company, suggesting internal confidence amid operational growth.
Phibro Animal Health Corp. director E. Thomas Corcoran recently acquired 10,000 shares of the company's Class A Common Stock on May 29, 2026, valued at $317,700. This transaction occurred while the stock was trading down significantly over the past week. The purchase comes against a backdrop where the firm reported strong financial results for the …
The recent activity of DuPont de Nemours, Inc. (NYSE:DD) CEO Lori Koch involving the sale of company common stock is occurring against a backdrop of significant corporate positive developments for DuPont. Ms. Koch executed two separate transactions in May and June 2026. Concurrently, the company reported strong first-quarter results that exceeded a…
Teresa Briggs, a director at DocuSign, Inc., executed multiple stock transactions in May and June 2026. She sold shares pursuant to a Rule 10b5-1 plan and simultaneously acquired shares resulting from the vesting of Restricted Stock Units (RSUs). Separately, she was granted additional RSUs. The company continues to announce significant technologica…
Docusign director James A. Beer executed a sale of common stock on June 2, 2026, through a pre-arranged trading plan. This transaction occurred as the company prepares for its earnings report. The article details Mr. Beer's recent vesting and granting of Restricted Stock Units (RSUs), alongside Docusign's major platform enhancements including new A…
Anna Marrs, a director at DocuSign, Inc., executed a sale of company common stock on June 2, 2026. This disposal was managed through a Rule 10b5-1 trading plan. The transaction occurred when the stock traded near $55.10, shortly before the release of earnings reports and following recent news regarding DocuSign's expansion into AI capabilities and …
Senior Vice President Claire Xu sold a portion of her NovaBridge Biosciences shares, while the company simultaneously reported encouraging data from its Phase 2a study for VIS-101 and received confirmation that its lead asset, givastomig, may qualify for accelerated FDA approval. Furthermore, NovaBridge appointed Mark Hagler as President and Chief …
